Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 13, 2007

Elixir and Siena Biotech to Evaluate SIRT1 Inhibitors in Huntington's Disease

  • Elixir Pharmaceuticals and Siena Biotech will work together on the optimization, validation, and evaluation of Elixir's SIRT1 inhibitors in Huntington's disease.

    SIRT1 is a member of the Sirtuin class of protein deacetylase enzymes. SIRT1 is the human equivalent of Sir2, a gene identified in yeast that plays a key role in the control of lifespan, metabolism, resistance to stress, and other cellular regulatory pathways.

    Elixir has over 20 Sirtuin patents and patent applications, which include coverage of small molecule SIRT1 inhibitors and activators. Siena Biotech has developed platforms for research on Huntington's disease and optimization of targeted small molecules against neurodegenerative disorders.

    Elixir will provide its SIRT1 small molecule inhibitors to Siena Biotech, which may modify these compounds using its medicinal chemistry and profiling capabilities. If optimized or second-generation compounds are produced from Siena's research, Elixir will screen the compounds through its assays to evaluate their degree of SIRT1 specificity. Siena Biotech will retain exclusive rights to any new compounds for use in neurodegenerative diseases. Elixir will hold the rights to all other disease areas.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »